Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Kirsten S. Vannice"'
Autor:
Fatima H. Al-Shimari, Camerin A. Rencken, Carl D. Kirkwood, Ramya Kumar, Kirsten S. Vannice, Barclay T. Stewart
Publikováno v:
BMC Public Health, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Introduction Hepatitis E virus (HEV) is the most common cause of acute hepatitis. While symptoms are generally mild and resolve within weeks, some populations (e.g., pregnant women, immunocompromised adults) are at high-risk of severe HEV-re
Externí odkaz:
https://doaj.org/article/5b0b8c6c8e1e4da9a88b322aba7a4d2e
Autor:
Tanya E. Libby, Miranda L.M. Delawalla, Fatima Al-Shimari, Calman A. MacLennan, Kirsten S. Vannice, Patricia B. Pavlinac
Publikováno v:
International Journal of Infectious Diseases, Vol 129, Iss , Pp 78-95 (2023)
Objectives: We conducted a systematic review of the longitudinal consequences of Shigella infection in children to inform the value proposition for an effective vaccine. Methods: We searched PubMed and Embase for studies published from January 01, 19
Externí odkaz:
https://doaj.org/article/7bd16ee3e933434fb5a469f0616405fe
Autor:
Kirsten S. Vannice, Susan L. Hills, Lauren M. Schwartz, Alan D. Barrett, James Heffelfinger, Joachim Hombach, G. William Letson, Tom Solomon, Anthony A. Marfin, the Japanese encephalitis vaccination experts panel
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
Vaccines against Japanese encephalitis (JE) have been available for decades. Currently, most JE-endemic countries have vaccination programs for their at-risk populations. Even so, JE remains the leading recognized cause of viral encephalitis in Asia.
Externí odkaz:
https://doaj.org/article/0f0d7e8409a3466190711403f7c6bec4
Autor:
Patricia B. Pavlinac, Elizabeth T. Rogawski McQuade, James A. Platts-Mills, Karen L. Kotloff, Carolyn Deal, Birgitte K. Giersing, Richard A. Isbrucker, Gagandeep Kang, Lyou-Fu Ma, Calman A. MacLennan, Peter Patriarca, Duncan Steele, Kirsten S. Vannice
Publikováno v:
Vaccines, Vol 10, Iss 4, p 489 (2022)
Vaccine candidates for Shigella are approaching phase 3 clinical trials in the target population of young children living in low- and middle-income countries. Key study design decisions will need to be made to maximize the success of such trials and
Externí odkaz:
https://doaj.org/article/7b3e5533178c4f4590b2b6df4fc7d8c0
Autor:
Anthony A Marfin, Lauren M Schwartz, James D. Heffelfinger, Alan D.T. Barrett, Joachim Hombach, Tom Solomon, Kirsten S Vannice, Susan L. Hills, G. William Letson
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
NPJ Vaccines
NPJ VACCINES
NPJ Vaccines
NPJ VACCINES
Vaccines against Japanese encephalitis (JE) have been available for decades. Currently, most JE-endemic countries have vaccination programs for their at-risk populations. Even so, JE remains the leading recognized cause of viral encephalitis in Asia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11163a48bc9ae3e731c2785bb87cf195
https://doaj.org/article/0f0d7e8409a3466190711403f7c6bec4
https://doaj.org/article/0f0d7e8409a3466190711403f7c6bec4
Autor:
Patricia B, Pavlinac, Elizabeth T, Rogawski McQuade, James A, Platts-Mills, Karen L, Kotloff, Carolyn, Deal, Birgitte K, Giersing, Richard A, Isbrucker, Gagandeep, Kang, Lyou-Fu, Ma, Calman A, MacLennan, Peter, Patriarca, Duncan, Steele, Kirsten S, Vannice
Publikováno v:
Vaccines. 10(4)
Vaccine candidates for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::67ac3d5107525dd5ab7127fce4b81acd
https://pubmed.ncbi.nlm.nih.gov/35455238
https://pubmed.ncbi.nlm.nih.gov/35455238
Autor:
Heidi Meyer, Alan D.T. Barrett, Birgitte K. Giersing, E. Griffiths, David Wood, David C. Kaslow, Anna P. Durbin, Joachim Hombach, Kirsten S. Vannice
Publikováno v:
Vaccine. 37:7443-7450
On 1 February 2016, in the context of the ongoing Zika virus epidemic, the WHO declared that the recently reported clusters of microcephaly and other neurological disorders constituted a Public Health Emergency of International Concern (PHEIC). In re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c7e199ce1b2ba1db145f28f42e8f932
https://doi.org/10.1016/j.vaccine.2016.10.034
https://doi.org/10.1016/j.vaccine.2016.10.034
Autor:
Joachim Hombach, Marco Cavaleri, Annelies Wilder-Smith, Robert W Eisinger, Ivana Knezevic, Kirsten S. Vannice, Hilary D. Marston, Philip R. Krause, M. Cristina Cassetti
Publikováno v:
Vaccine
Since its peak in early 2016, the incidence of Zika virus (ZIKV) cases has declined to such low levels that Phase 3 field efficacy trials may be infeasible. While great progress was made to rapidly advance several vaccine candidates into Phase 1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f27b16f5b0cc0a03d81edd5943113783
https://doi.org/10.1016/j.vaccine.2018.12.040
https://doi.org/10.1016/j.vaccine.2018.12.040
Autor:
Wellington Sun, Pete Smith, Annelies Wilder-Smith, Stephen J. Thomas, Kalinka Carrijo, Alan D.T. Barrett, Anna P. Durbin, Kirsten S. Vannice, Eva Harris, Tim Endy, Marco Cavaleri, Aravinda M. de Silva, Leah C. Katzelnick, Joachim Hombach, Bruce L. Innis
Publikováno v:
Vaccine. 36:3411-3417
Licensing and decisions on public health use of a vaccine rely on a robust clinical development program that permits a risk-benefit assessment of the product in the target population. Studies undertaken early in clinical development, as well as well-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d3971736fc729d66e767b0a9dcc27d9
https://doi.org/10.1016/j.vaccine.2018.02.062
https://doi.org/10.1016/j.vaccine.2018.02.062
Autor:
Anna Lena Lopez, Pete Smith, Expedito José de Albuquerque Luna, Edwin J. Asturias, In-Kyu Yoon, Ira M. Longini, Ole Wichmann, Hasitha Tissera, Joachim Hombach, Kirsten S. Vannice
Publikováno v:
Vaccine. 35:5535-5542
Since December 2015, the first dengue vaccine has been licensed in several Asian and Latin American countries for protection against disease from all four dengue virus serotypes. While the vaccine demonstrated an overall good safety and efficacy prof
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355dd4eb4861db93d2d4d0263e694480
https://doi.org/10.1016/j.vaccine.2017.08.066
https://doi.org/10.1016/j.vaccine.2017.08.066